Galactosylceramidase (GALC) is the lysosomal β-galactosidase responsible for the hydrolysis of galactosylceramide. Inherited deficiency in GALC causes Krabbe disease, a devastating neurological disorder characterized by accumulation of galactosylceramide and its deacylated counterpart, the toxic sphingoid base galactosylsphingosine (psychosine). We report the design and application of a fluorescently tagged activity-based probe (ABP) for the sensitive and specific labeling of active GALC molecules from various species. The probe consists of a β-galactopyranose-configured cyclophellitol-epoxide core, conferring specificity for GALC, equipped with a BODIPY fluorophore at C6 that allows visualization of active enzyme in cells and tissues. Detection of residual GALC in patient fibroblasts holds great promise for laboratory diagnosis of Krabbe disease. We further describe a procedure for in situ imaging of active GALC in murine brain by intra-cerebroventricular infusion of the ABP. In conclusion, this GALC-specific ABP should find broad applications in diagnosis, drug development, and evaluation of therapy for Krabbe disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cbic.201600561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ablation of lipocalin-2 reduces neuroinflammation in a mouse model of Krabbe disease.
Sci Rep
December 2024
Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14214, USA.
Lipocalin-2 (LCN2) is an acute-phase secretory molecule significantly upregulated in various neuroinflammatory and demyelinating conditions. Krabbe disease (KD) is a neurodegenerative lysosomal disorder caused by a galactosylceramidase (GALC) deficiency, accumulating cytotoxic psychosine in nervous systems, and subsequent neuroinflammation. Here, we show that LCN2 is highly overexpressed in GALC-deficient astrocytes.
View Article and Find Full Text PDFA lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.
Mol Ther Nucleic Acids
December 2024
Department of Therapeutics for Multiple System Atrophy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Article Synopsis
- The study highlights the challenge of delivering mRNA therapies effectively into oligodendrocytes, a type of brain cell, as traditional viral vectors aren't effective.
- Researchers utilized LUNAR lipid nanoparticles to achieve high efficiency and specificity in delivering mRNA to these cells, leveraging low-density lipoprotein receptors with the help of apoprotein E.
- A single dose of LUNAR-human galactosylceramidase mRNA significantly improved the health and survival of twitcher mice, a model for Krabbe disease, showcasing the potential of this method for treating neurological disorders related to oligodendrocytes.
Human iPSC-derived myelinating organoids and globoid cells to study Krabbe disease.
PLoS One
December 2024
Departments of Biochemistry and Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Article Synopsis
- - Krabbe disease (Kd) is caused by a deficiency in the enzyme GALC, leading to the accumulation of the lipid galactosylceramide (GalCer), which produces a toxic lipid called psychosine that damages myelinating cells and leads to demyelination.
- - Research using induced pluripotent stem cells (iPSCs) from Kd patients revealed that Kd myelinating organoids exhibit early myelination defects without affecting other cell types, while the microglia in these organoids show changes in response to GalCer feeding.
- - The findings suggest that while Kd model organoids don't show classic lysosomal dysfunction, they provide an essential platform for studying the mechanisms behind demyel
Lifestyle factors and incident multimorbidity related to chronic disease: a population-based cohort study.
Eur J Ageing
November 2024
Department of Epidemiology, University Medical Center Groningen, University of Groningen, PO Box 30.001 (FA40), 9700 RB, Groningen, the Netherlands.
Background: Multimorbidity is linked to poor quality of life, and increased healthcare costs, and multimorbidity risk is potentially mitigated by a healthy lifestyle. This study evaluated the individual and joint contributions of an extensive set of lifestyle factors to the development of multimorbidity.
Methods: A prospective study of 133,719 adults (age 45.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!